The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) - an antibody-guided drug - for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening...
More...